Recent advances in systematic therapy of breast cancer: Chinese contribution for international progress.
作者信息
Wang Yan, Xu Binghe
机构信息
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
出版信息
Chin J Cancer Res. 2024 Dec 30;36(6):587-591. doi: 10.21147/j.issn.1000-9604.2024.06.01.
Abstract
摘要
相似文献
1
Recent advances in systematic therapy of breast cancer: Chinese contribution for international progress.乳腺癌系统治疗的最新进展：中国对国际进展的贡献。
Chin J Cancer Res. 2024 Dec 30;36(6):587-591. doi: 10.21147/j.issn.1000-9604.2024.06.01.
2
Recent advances in caspase-3, breast cancer, and traditional Chinese medicine: a review.近年来 Caspase-3、乳腺癌和中医药的研究进展：综述
J Chemother. 2024 Sep;36(5):370-388. doi: 10.1080/1120009X.2023.2278014. Epub 2023 Nov 7.
3
Recent Advances in Immunotherapy for Breast Cancer: A Review.乳腺癌免疫治疗的最新进展：综述
Breast Cancer (Dove Med Press). 2024 Aug 27;16:497-516. doi: 10.2147/BCTT.S482504. eCollection 2024.
4
[Guidelines for clinical diagnosis and treatment of advanced triple negative breast cancer in China（2024 edition）].中国晚期三阴性乳腺癌临床诊疗指南（2024年版）
Zhonghua Zhong Liu Za Zhi. 2024 Mar 22;46(0):471-480. doi: 10.3760/cma.j.cn112152-20240118-00034.
5
Progress in diagnosis of breast cancer: Advances in radiology technology.乳腺癌诊断进展：放射学技术的进步
Asia Pac J Oncol Nurs. 2015 Jul-Sep;2(3):186-191. doi: 10.4103/2347-5625.158017.
6
Biomarkers of the metabolic syndrome and breast cancer prognosis.代谢综合征生物标志物与乳腺癌预后。
Cancers (Basel). 2010 Apr 28;2(2):721-39. doi: 10.3390/cancers2020721.
7
Wnt/-catenin signalling pathway in breast cancer cells and its effect on reversing tumour drug resistance by alkaloids extracted from traditional Chinese medicine.Wnt/-catenin 信号通路在乳腺癌细胞中的作用及其对逆转肿瘤耐药性的影响，该作用是通过从中药中提取的生物碱实现的。
Expert Rev Mol Med. 2023 Jun 19;25:e21. doi: 10.1017/erm.2023.16.
8
Latest research progress in the correlation between baicalein and breast cancer invasion and metastasis.黄芩素与乳腺癌侵袭和转移相关性的最新研究进展
Mol Clin Oncol. 2016 Apr;4(4):472-476. doi: 10.3892/mco.2016.750. Epub 2016 Jan 28.
9
Recent advances in breast cancer biology.乳腺癌生物学的最新进展。
Curr Opin Oncol. 1998 Nov;10(6):486-91. doi: 10.1097/00001622-199811000-00002.
10
[Research progress on traditional Chinese medicine compounds combined with external therapy in treatment of hyperplasia of mammary glands].中药复方联合外治法治疗乳腺增生的研究进展
Zhongguo Zhong Yao Za Zhi. 2023 Jun;48(11):2856-2867. doi: 10.19540/j.cnki.cjcmm.20230315.601.
引用本文的文献
1
Multi-omics profile of exceptional long-term survivors of AJCC stage III triple-negative breast cancer.美国癌症联合委员会（AJCC）III期三阴性乳腺癌长期生存者的多组学特征
Chin J Cancer Res. 2025 Jun 30;37(3):316-336. doi: 10.21147/j.issn.1000-9604.2025.03.03.
本文引用的文献
1
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.基于整合 mRNA-lncRNA 特征的高危可手术三阴性乳腺癌患者强化化疗与标准化疗的比较（BCTOP-T-A01）：一项随机、多中心、III 期试验。
BMJ. 2024 Oct 23;387:e079603. doi: 10.1136/bmj-2024-079603.
2
Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors.ESG401（一种 Trop2 抗体药物偶联物）治疗局部晚期/转移性实体瘤患者的 1a 期研究。
Cell Rep Med. 2024 Sep 17;5(9):101707. doi: 10.1016/j.xcrm.2024.101707. Epub 2024 Aug 30.
3
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial.节拍化疗联合抗 PD-1 治疗转移性乳腺癌：一项贝叶斯自适应 2 期随机试验。
Nat Med. 2024 Sep;30(9):2528-2539. doi: 10.1038/s41591-024-03088-2. Epub 2024 Jul 5.
4
Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study.迪西他单抗维地昔妥珠单抗，一种 HER2 靶向抗体药物偶联物，用于 HER2 过表达和 HER2 低表达的晚期乳腺癌患者：一项 I/ Ib 期研究。
Cancer Commun (Lond). 2024 Jul;44(7):833-851. doi: 10.1002/cac2.12577. Epub 2024 Jun 28.
5
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.SHR-A1811 治疗人表皮生长因子受体 2 表达或突变的晚期实体瘤的安全性、有效性和药代动力学：一项全球 I 期临床试验
J Clin Oncol. 2024 Oct 10;42(29):3453-3465. doi: 10.1200/JCO.23.02044. Epub 2024 Jun 20.
6
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).第六和第七版晚期乳腺癌国际共识诊治指南（ABC 指南 6 和 7）。
Breast. 2024 Aug;76:103756. doi: 10.1016/j.breast.2024.103756. Epub 2024 May 28.
7
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial.FS-1502，一种靶向 HER2 的抗体药物偶联物，用于治疗 HER2 表达的转移性乳腺癌：一项 1a/1b 期临床试验。
Nat Commun. 2024 Jun 17;15(1):5158. doi: 10.1038/s41467-024-48798-w.
8
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.曲妥珠单抗-德鲁替康与医生选择的治疗方案用于治疗既往治疗的亚洲 HER2 低表达不可切除/转移性乳腺癌患者：DESTINY-Breast04 研究的亚组分析。
Breast Cancer. 2024 Sep;31(5):858-868. doi: 10.1007/s12282-024-01600-7. Epub 2024 Jun 17.
9
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
10
Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial.曲妥珠单抗新辅助-辅助治疗 HER2 阳性早期乳腺癌：PEONY 随机 III 期试验的最终分析。
Nat Commun. 2024 Mar 9;15(1):2153. doi: 10.1038/s41467-024-45591-7.
Zotero 插件